Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tofacitinib citrate Clear all
Completed Phase 2 Interventional Results available

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
24
States / cities
Upland, California • Clearwater, Florida • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 26, 2026, 2:50 PM EDT
Completed No phase listed Observational Results available

Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

NCT03964649
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
7,308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

A Study Of CP-690,550 In Stable Kidney Transplant Patients

NCT01710033
View directory record Official record
Conditions
Kidney Transplant
Interventions
Placebo, CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 26, 2026, 2:50 PM EDT
Completed No phase listed Observational Results available

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

NCT00414661
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
21
States / cities
Gilbert, Arizona • Tucson, Arizona • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2013 · Synced Oct 26, 2026, 2:50 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 26, 2026, 2:50 PM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 26, 2026, 2:50 PM EDT
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective

NCT02566967
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib
Drug
Lead sponsor
Norman B. Gaylis, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

NCT01484561
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550 or Placebo, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
South Miami, Florida • Albany, New York • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT00969813
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Tofacitinib in Recurrent GBM Patients

NCT05326464
View directory record Official record
Conditions
Glioblastoma
Interventions
Tofacitinib 10mg, Temozolomide, Lomustine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 26, 2026, 2:50 PM EDT
Active, not recruiting Phase 2 Interventional

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

NCT03681275
View directory record Official record
Conditions
Diaphragm Injury
Interventions
Tofacitinib 10 MG [Xeljanz], Placebo to match Tofacitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Of Tofacitinib In Pediatric JIA Population

NCT02592434
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

NCT04111614
View directory record Official record
Conditions
Healthy
Interventions
Tofacitinib tablet, Tofacitinib Oral Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT01393899
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Anaheim, California • Cypress, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

NCT01500551
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
43
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT03274076
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Tofacitinib, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 26, 2026, 2:50 PM EDT
Terminated Early Phase 1 Interventional

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

NCT03159936
View directory record Official record
Conditions
Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Interventions
Tofacitinib citrate
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

NCT01039688
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Disease-modifying antirheumatic drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

Study of Tofacitinib in Refractory Dermatomyositis

NCT03002649
View directory record Official record
Conditions
Dermatomyositis
Interventions
Tofacitinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 26, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 26, 2026, 2:50 PM EDT